Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:345012.
doi: 10.1155/2011/345012. Epub 2011 Nov 15.

Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients

John F Pohl  1 , Raza Patel, Jeffery T Zobell, Ellen Lin, E Kent Korgenski, Kody Crowell, Mark W Mackay, Aleesha Richman, Christian Larsen, Barbara A Chatfield
Affiliations

Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients

John F Pohl et al. Gastroenterol Res Pract. 2011.

Abstract

Children with cystic fibrosis (CF) often take proton pump inhibitors (PPIs), which helps improve efficacy of fat absorption with pancreatic enzyme replacement therapy. However, PPI use is known to be associated with Clostridium difficile-(C. diff-) associated diarrhea (CDAD). We retrospectively evaluated the incidence of C. diff infection from all pediatric hospital admissions over a 5-year period at a single tertiary children's hospital. We found significantly more C. diff-positive stool tests in hospitalized patients with CF compared to patients with no diagnosis of CF. However, use of a PPI was not associated with an increased risk of CDAD in hospitalized CF patients. In summary, C. diff infection is more common in hospitalized pediatric CF patients although PPI use may not be a risk factor for CDAD development in this patient population.

PubMed Disclaimer

References

    1. Novak KJ. Cystic fibrosis. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, editors. Pharmacotherapy Principles and Practice. New York, NY, USA: McCraw-Hill; 2008.
    1. Hendriks H, Kreel B, Forget P. Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition. 2001;33(3):260–265. - PubMed
    1. Proesmans M, Omeprazole BK. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. European Journal of Pediatrics. 2003;162(11):760–763. - PubMed
    1. Pohl JF. Nutrition in cystic fibrosis. Practical Gastroenterology. 2010;34(3):20–27.
    1. Tran T, van den Neucker A, Hendriks J, Forget P, Forget PP. Effects of a proton-pump inhibitor in cystic fibrosis. Acta Paediatrica. 1998;87(5):553–558. - PubMed

LinkOut - more resources